Discovery of Inositol(1,4,5)trisphosphate Receptor Inhibitors

Information

  • Research Project
  • 7406906
  • ApplicationId
    7406906
  • Core Project Number
    R43NS049920
  • Full Project Number
    1R43NS049920-01A2
  • Serial Number
    49920
  • FOA Number
    PA-07-80
  • Sub Project Id
  • Project Start Date
    1/15/2008 - 17 years ago
  • Project End Date
    12/31/2009 - 15 years ago
  • Program Officer Name
    FERTIG, STEPHANIE
  • Budget Start Date
    1/15/2008 - 17 years ago
  • Budget End Date
    12/31/2009 - 15 years ago
  • Fiscal Year
    2008
  • Support Year
    1
  • Suffix
    A2
  • Award Notice Date
    1/14/2008 - 17 years ago

Discovery of Inositol(1,4,5)trisphosphate Receptor Inhibitors

[unreadable] DESCRIPTION (provided by applicant): Stroke has become a significant cause of mortality and morbidity among elderly people in industrialized countries. To address the growing burden of health care costs and the immeasurable emotional toll on families as well as affected individuals, new pharmacological agents for prevention and treatment are desperately needed. Oxygen deprivation and oxidative stress lead to release of cytochrome c, which is related in turn to the activation of Ins(1,4,5)P3 receptors (IP3R) controlling calcium release from intracellular stores. Therefore, small molecule antagonists of IP3R would be attractive therapeutic candidates to restore proper calcium signaling pathways and prevent apoptosis. To establish the feasibility of this approach, Echelon Biosciences proposes to synthesize and identify potential IP3 antagonists. Specifically, we will use in silico modeling in combination with chemical library synthesis to prepare phosphate-free IP3 mimetics that dock in the ligand binding site, as well as a series of xestospongin (a potent natural IP3R inhibitor) analogs. Candidate compounds will be screened using a medium throughput in-cell fluorescence-based assay in which the time course for calcium release by IP3 in appropriately stimulated cells is monitored in Fluo-3 plus drug-treated fibroblasts. Activity will be optimized by iterative cycles of modeling and synthesis based on biological activities observed. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R43
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    93749
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    NINDS:93749\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ECHELON BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SALT LAKE CITY
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    84108
  • Organization District
    UNITED STATES